» Articles » PMID: 22267018

What's Love Got to Do with It? Explaining Adherence to Oral Antiretroviral Pre-exposure Prophylaxis for HIV-serodiscordant Couples

Overview
Date 2012 Jan 24
PMID 22267018
Citations 172
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Adherence may be the "Achilles heel" of pre-exposure prophylaxis (PrEP), a promising biomedical approach to HIV prevention. This article presents an explanation of PrEP adherence for African serodiscordant couples derived from qualitative data.

Design: Explaining quantitative findings is one way qualitative investigation contributes to research in medicine and public health. This qualitative interview study was nested in the Partners PrEP Study, a phase III randomized trial evaluating oral tenofovir and emtricitabine/tenofovir PrEP to prevent HIV acquisition by HIV-uninfected partners in serodiscordant heterosexual couples.

Methods: In-depth qualitative interviews were provided by 60 Partners PrEP Study participants in Uganda. Interviews used open-ended questions eliciting information on adherence experiences, barriers, and facilitators. An inductive approach informed by grounded theory methodology was used to analyze study data.

Results: The proposed explanation may be summarized as follows. Serodiscordance destabilizes couples, as the HIV-negative partner reacts with anger, fear, and sadness to the implication of infidelity represented by HIV infection. A "discordance dilemma" ensues, as the desire to avoid acquiring HIV and the advantages of preserving the relationship become competing priorities. PrEP is seen as a solution-a means of safeguarding health without ending the relationship. PrEP users benefit from the support of partners, who reinforce adherence. Where discord in the relationship persists, adherence suffers.

Conclusions: PrEP adherence in serodiscordant couples may be understood as a function of the desire to reduce risk although preserving a partnered relationship. PrEP use in stable couples may be associated with improved adherence and thus, greater effectiveness.

Citing Articles

Hoping to Adhere? Examining the Relationship Between Hope and Pre-exposure Prophylaxis Willingness, Adherence, and Persistence Among Young Women in South Africa and Zimbabwe (HPTN 082).

Gichane M, Velloza J, Hosek S, Beauchamp G, Anderson P, Delany-Moretlwe S AIDS Behav. 2024; 29(2):527-534.

PMID: 39446266 PMC: 11814051. DOI: 10.1007/s10461-024-04536-3.


Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084.

Tolley E, Bula A, Chitukuta M, Ndimande-Khoza N, Etima J, Namey E PLoS One. 2024; 19(10):e0309811.

PMID: 39441777 PMC: 11498703. DOI: 10.1371/journal.pone.0309811.


Factors Associated with Usage of Oral-PrEP among Female Sex Workers in Nairobi, Kenya, Assessed by Self-Report and a Point-of-Care Urine Tenofovir Immunoassay.

Shah P, Spinelli M, Irungu E, Kabuti R, Ngurukiri P, Babu H AIDS Behav. 2024; 28(11):3836-3849.

PMID: 39136824 PMC: 11471708. DOI: 10.1007/s10461-024-04455-3.


Demonstrating service delivery models for effective initiation and retention on pre-exposure prophylaxis (PrEP) among female bar workers in Dar es Salaam, Tanzania: A double randomized intervention study protocol.

Chebet J, Akyoo W, Goymann H, Harling G, Barnhart D, Mosha I PLoS One. 2024; 19(6):e0304077.

PMID: 38935796 PMC: 11210872. DOI: 10.1371/journal.pone.0304077.


How PrEP delivery was integrated into public ART clinics in central Uganda: A qualitative analysis of implementation processes.

Wyatt M, Pisarski E, Nalumansi A, Kasiita V, Kamusiime B, Nalukwago G PLOS Glob Public Health. 2024; 4(3):e0002916.

PMID: 38452111 PMC: 10919847. DOI: 10.1371/journal.pgph.0002916.


References
1.
Stirratt M, Gordon C . Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 2008; 5(4):186-92. DOI: 10.1007/s11904-008-0027-z. View

2.
Abdool Karim Q, Abdool Karim S, Frohlich J, Grobler A, Baxter C, Mansoor L . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74. PMC: 3001187. DOI: 10.1126/science.1193748. View

3.
Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

4.
Abdool Karim S, Kashuba A, Werner L, Abdool Karim Q . Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011; 378(9787):279-81. PMC: 3652579. DOI: 10.1016/S0140-6736(11)60878-7. View